Showing 861-870 of 21415 results for "".
- Post-Pandemic US Cardiovascular Death Rate on Risehttps://reachmd.com/news/post-pandemic-us-cardiovascular-death-rate-on-rise/2456943/Ann Arbor, January 24, 2024 – New research confirms what public health leaders have been fearing: the significant uptick in the cardiovascular disease (CVD) death rate that began in 2020 has continued. The continuing trend reverses improvements achieved in the decade before the COV
- STRIDE-13 Finds V116 Immunogenic in At-Risk Children and Adolescentshttps://reachmd.com/news/stride-13-finds-v116-immunogenic-in-at-risk-children-and-adolescents/2487779/Key Takeaways V116 was associated with noninferior responses for serotypes shared with PPSV23 and stronger responses for serotypes unique to V116. The study enrolled previously vaccinated children and adolescents aged 2 to <18 years with diabetes me
- Study: Semaglutide Improves PASI Scoreshttps://reachmd.com/news/study-semaglutide-improves-pasi-scores/2484098/Semaglutide may offer dual dermatologic and metabolic benefits in patients with psoriasis and obesity, even in the absence of diabetes, according to a 6-month prospective cohort study in Clinical and Experimental Dermatology.
- Exploring the Impact of Cortisol Regulation on Overall Healthhttps://reachmd.com/news/exploring-the-impact-of-cortisol-regulation-on-overall-health/2473866/Cutting-edge discoveries from the discipline of Diabetes and Endocrinology highlight that hormonal regulation is a sophisticated process. Researchers have recognized a complex link between cortisol regulation and overall health outcomes. While a reduction in cortis
- Revolutionizing Diabetes Care: How Real-Time Video Consultations Are Bridging Primary and Secondary Carehttps://reachmd.com/news/revolutionizing-diabetes-care-how-real-time-video-consultations-are-bridging-primary-and-secondary-care/2473889/As the demands of chronic disease management grow more complex, technology is stepping in not as a novelty, but as a necessity. Among these tools, video conferencing has emerged as a critical bridge between primary and secondary care—transforming the way clinicians
- Study Finds Cardiovascular Disease Risk Can Develop Decades Earlier in People with Diabetes and Kidney Diseasehttps://reachmd.com/news/study-finds-cardiovascular-disease-risk-can-develop-decades-earlier-in-people-with-diabetes-and-kidney-disease/2468620/New research presented at the American Heart Association’s Scientific Sessions 2024 has revealed a troubling link between cardiovascular-kidney-metabolic (CKM) syndrome and early cardiovascular disease (CVD) risk. CKM syndrome—a condition characterized by the connections between cardiovascular di
- Want to Prevent Diabetes? Stop Eating So Much of This One Food, Harvard Experts Sayhttps://reachmd.com/news/want-to-prevent-diabetes-stop-eating-so-much-of-this-one-food-harvard-experts-say/2467780/Burger lovers may flip out over this news. A new Harvard study establishes a “significant” link between a key component in
- Diabetes and Obesity Can Damage the Liver to the Point of Failure – But Few People Know Their Risk of Developing Liver Diseasehttps://reachmd.com/news/diabetes-and-obesity-can-damage-the-liver-to-the-point-of-failure-but-few-people-know-their-risk-of-developing-liver-disease/2467588/Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Fo
- Researchers Find GLP-1 Medications Safe to Continue Before Surgery in Patients with Diabetes and Obesityhttps://reachmd.com/news/researchers-find-glp-1-medications-safe-to-continue-before-surgery-in-patients-with-diabetes-and-obesity/2466941/Credit: American Journal of Gastroenterology (2024). DOI: 10.14309/ajg.0000000000002820 In a meta-analysis and review
- Afrezza ADA 2026 Announcement Highlights Pediatric, Pregnancy, and AID Datahttps://reachmd.com/news/afrezza-ada-2026-announcement-highlights-pediatric-pregnancy-and-aid-data/2487315/Key Takeaways Four Afrezza analyses are slated for ADA 2026 across youth diabetes, gestational diabetes, and automated insulin delivery use. The pediatric work draws from INHALE-1, comparing inhaled insulin with rapid-acting analogs in youth with basel